EP854 - ECE_3854 - Off-label use of semaglutide (Ozempic®) for weight reduction: a real-world case series of 20 patients
Obesity is a chronic metabolic condition closely linked to insulin resistance and increased cardiometabolic risk. While semaglutide 2.4 mg is specifically approved for obesity treatment, lower doses of semaglutide (Ozempic®) are frequently used off-label for weight reduction in everyday clinical practice. However...